According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Oxytocin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.5	28.09.2024	9374040-00009	Date of first issue: 27.08.2021

#### **SECTION 1:** Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Oxytocin Formulation
1.2	Relevant identified uses of th	e s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture		Veterinary product
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD Walton Manor, Walton MK7 7AJ Milton Keynes - United Kingdom
	Telephone	:	+1-908-740-4000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

#### **1.4 Emergency telephone number**

+1-908-423-6000

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Not a hazardous substance or mixture.

#### 2.2 Label elements

# Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Oxytocin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.5	28.09.2024	9374040-00009	Date of first issue: 27.08.2021

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Oxytocin, monoacetate (salt)	6233-83-6 228-347-5	Acute Tox. 4; H302 Repr. 1A; H360D Aquatic Chronic 4; H413	>= 0.0002 - < 0.0025

For explanation of abbreviations see section 16.

#### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

Protection of first-aiders	:	No special precautions are necessary for first aid responders.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap as a precaution. Get medical attention if symptoms occur.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

None known.

# 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Oxytocin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.5	28.09.2024	9374040-00009	Date of first issue: 27.08.2021

#### **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

	Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
	Unsuitable extinguishing media	:	None known.
5.2	Special hazards arising from	the	e substance or mixture
	Specific hazards during fire- fighting	:	Exposure to combustion products may be a hazard to health.
	Hazardous combustion prod- ucts	:	No hazardous combustion products are known
5.3	Advice for firefighters		
	Special protective equipment for firefighters	:	Wear self-contained breathing apparatus for firefighting if nec- essary. Use personal protective equipment.
	Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment.

SO. Evacuate area.

#### **SECTION 6: Accidental release measures**

6.1 Personal precautions, protective equipment and emergency procedures						
Personal precautions	:	Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).				
6.2 Environmental precautions						
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. If spillage enters rivers or watercourses, inform the Environ- ment Agency (emergency telephone number 0800 807060).				

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up	:	Soak up with inert absorbent material.
		For large spills, provide dyking or other appropriate contain-
		ment to keep material from spreading. If dyked material can

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Oxytocin Formulation**

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
3.5		9374040-00009	Date of first issue: 27.08.2021
		Clean up remain bent. Local or nationa posal of this ma employed in the mine which regu Sections 13 and	re recovered material in appropriate container. hing materials from spill with suitable absor- al regulations may apply to releases and dis- terial, as well as those materials and items e cleanup of releases. You will need to deter- ulations are applicable. In 15 of this SDS provide information regarding mational requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

#### **SECTION 7: Handling and storage**

7.1 Precautions for safe handling						
Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.				
Local/Total ventilation	:	Use only with adequate ventilation.				
Advice on safe handling	:	Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Take care to prevent spills, waste and minimize release to the environment.				
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.				
7.2 Conditions for safe storage,	inc	luding any incompatibilities				
Requirements for storage areas and containers	:	Keep in properly labelled containers. Store in accordance with the particular national regulations.				
Advice on common storage	:	Do not store with the following product types: Strong oxidizing agents Gases				
7.3 Specific end use(s)						
Specific use(s)	:	No data available				

### 7.1 Precautions for safe handling

### **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

#### **Occupational Exposure Limits**



Internal

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

# Oxytocin Formulation

Ver 3.5	Version Revision Date: 3.5 28.09.2024			Number: 1040-00009		te of last issue: 06.04.2024 te of first issue: 27.08.2021	
Components		CAS-No.	Value type (Fo of exposure)	rm	Control parameters	Basis	
	Oxytoo	in, mono-	6233-83-6	STEL		50 ng/m3 (OEB 5)	Internal

500 ng/100 cm<sup>2</sup>

Wipe limit

#### 8.2 Exposure controls

acetate (salt)

#### **Engineering measures**

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

#### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Material	:	Chemical-resistant gloves
Remarks Skin and body protection	:	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	No personal respiratory protective equipment normally re- quired.

#### **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

Appearance	:	liquid
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Oxytocin Formulation**

Ver 3.5	sion	Revision Date: 28.09.2024		S Number: 74040-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
	range Flash p	point	:	No data available	9
	Evapo	ration rate	:	No data available	9
	Flamm	ability (solid, gas)	:	Not applicable	
		explosion limit / Upper ability limit	:	No data available	9
		explosion limit / Lower ability limit	:	No data available	9
	Vapou	r pressure	:	No data available	9
	Relativ	e vapour density	:	No data available	9
	Relativ	e density	:	No data available	9
	Density	y	:	No data available	9
	Partitic octano	ter solubility on coefficient: n-	:	No data available Not applicable No data available	
	Decom	position temperature	:	No data available	9
	Viscos Viso	ity cosity, kinematic	:	No data available	e
	Explos	ive properties	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
9.2		n <b>formation</b> ability (liquids)	:	No data available	9
	Molecu	ular weight	:	No data available	9
	Particle	e size	:	Not applicable	

### **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Oxytocin Formulation**

Revision Date: 28.09.2024	SDS Number: 9374040-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021				
10.3 Possibility of hazardous reactions						
Hazardous reactions : Can react with strong oxidizing agents.						
tions to avoid						
ions to avoid	: None known.					
natible materials						
als to avoid	: Oxidizing agen	ts				
-	-					
•	•					
······						
-						
-	f : Inhalation Skin contact					
	Ingestion					
toxicity	Lyc contact					
•	able information.					
onents:						
•	•					
oral toxicity	: LD50 (Mouse): :	> 514 mg/kg				
	LD50 (Rat): > 2 <sup>-</sup>	1 mg/kg				
toxicity (other routes o stration)		> 514 mg/kg te: Subcutaneous				
		1 mg/kg te: Subcutaneous				
	LD50 (Rat): 2.3 Application Rou					
	28.09.2024 bility of hazardous re dous reactions tions to avoid ions to avoid patible materials als to avoid dous decomposition cardous decomposition 11: Toxicological in nation on toxicological ation on likely routes of toxicity assified based on availa <u>onents:</u> cin, monoacetate (sal oral toxicity	28.09.2024       9374040-00009         bility of hazardous reactions       Can react with         dous reactions       : Can react with         tions to avoid       : None known.         ions to avoid       : None known.         opatible materials       als to avoid       : Oxidizing agen         dous decomposition products       cardous decomposition products are known.         11: Toxicological information       nation on toxicological effects         ation on likely routes of :       Inhalation         ure       :       Inhalation         ssified based on available information.       Eye contact         onents:       information.         cin, monoacetate (salt):       information.         oral toxicity       :       LD50 (Mouse)::         toxicity (other routes of :       LD50 (Mouse)::         toxicity (other routes of :       LD50 (Mouse)::         toxicity (other routes of :       LD50 (Mouse)::         Application Rou       LD50 (Rat): > 2'         Application Rou       LD50 (Rat): > 2'				

Not classified based on available information.

#### Serious eye damage/eye irritation

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Oxytocin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.5	28.09.2024	9374040-00009	Date of first issue: 27.08.2021

#### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

#### Oxytocin, monoacetate (salt):

Genotoxicity in vitro : Test Type: Chromosomal aberration Test system: Human lymphocytes Result: negative

#### Carcinogenicity

Not classified based on available information.

#### Reproductive toxicity

Not classified based on available information.

#### **Components:**

#### Oxytocin, monoacetate (salt):

Effects on foetal develop- ment	:	Test Type: Development Species: Rat Application Route: Subcutaneous Developmental Toxicity: NOAEL: 1 mg/kg body weight Result: No effects on foetal development
------------------------------------	---	---

Reproductive toxicity - As- : May damage the unborn child. sessment

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

#### Components:

#### Oxytocin, monoacetate (salt):

Species	:	Rat
LÕAEL	:	5 µg/kg
Application Route	:	Subcutaneous
Exposure time	:	5 Days
Target Organs	:	Endocrine system

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Oxytocin Formulation**

Version 3.5	Revision Date: 28.09.2024	SDS Number: 9374040-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
-	r <b>ation toxicity</b> lassified based on av	ailable information.	
Expe	rience with human e	exposure	
Com	ponents:		
Oxyt	ocin, monoacetate (	salt):	
Inhali		Symptoms: beh Target Organs: Symptoms: Inc mia., hypotensi Target Organs: Symptoms: Nat : Target Organs: Symptoms: beh Target Organs: Symptoms: Inc mia., hypotensi	Central nervous system lavioral abnormalities Cardio-vascular system reased heart rate, May cause cardiac arrhyth- on, tachycardia, flushing Gastrointestinal tract

#### **SECTION 12: Ecological information**

#### 12.1 Toxicity

#### **Components:**

#### Oxytocin, monoacetate (salt):

#### Ecotoxicology Assessment

Acute aquatic toxicity	:	Toxic effects cannot be excluded
Chronic aquatic toxicity	:	Toxic effects cannot be excluded

#### 12.2 Persistence and degradability

No data available

#### 12.3 Bioaccumulative potential

#### **Components:**

#### Oxytocin, monoacetate (salt):

Partition coefficient: n- : log Pow: 6.27 octanol/water

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment

: This substance/mixture contains no components considered

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Oxytocin Formulation**

	very	persistent ar	stent, bioaccumulative and toxic (PBT), or ad very bioaccumulative (vPvB) at levels of
verse effects			
disrupting poten-	ered	to have end	ixture does not contain components consid- ocrine disrupting properties for environment REACH Article 57(f).
	verse effects e disrupting poten-	very 0.1% verse effects e disrupting poten- : This ered	very persistent an 0.1% or higher. verse effects e disrupting poten- : This substance/m ered to have endo

13.1 Waste treatment methods	
Product	<ul> <li>Dispose of in accordance with local regulations.</li> <li>According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.</li> <li>Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.</li> <li>Do not dispose of waste into sewer.</li> </ul>
Contaminated packaging	: Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

#### **SECTION 14: Transport information**

#### 14.1 UN number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.3 Transport hazard class(es)		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Oxytocin Formulation**

Vers 3.5	ion	Revision Date: 28.09.2024		OS Number: 74040-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021			
	IMDG		:	Not regulated as a	a dangerous good			
	ΙΑΤΑ		:	Not regulated as a	a dangerous good			
14.4	14.4 Packing group							
	ADN		:	Not regulated as a	a dangerous good			
	ADR		:	Not regulated as a	a dangerous good			
	RID		:	Not regulated as a	a dangerous good			
	IMDG		:	Not regulated as a	a dangerous good			
	IATA (	Cargo)	:	Not regulated as a	a dangerous good			
	IATA (	Passenger)	:	Not regulated as a	a dangerous good			
14.5	14.5 Environmental hazards							
	Not regulated as a dangerous good							
14.6 Special precautions for user								
	Not app	olicable						
14.7 Transport in bulk according to Annex II of Marpol and the IBC Code								
	Remar	ks	:	Not applicable for	product as supplied.			

### **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17)	:	Not applicable
UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation	:	Not applicable
The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Brit- ain)	:	Not applicable
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable
UK REACH List of substances subject to authorisation (Annex XIV)	:	Not applicable
GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation	:	Not applicable
Control of Major Accident Hazards Regulations 2015 (CC Not applicable	IVIA	NH)

The components of this product are reported in the following inventories:				
AICS	:	not determined		
DSL	:	not determined		

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.5	28.09.2024	9374040-00009	Date of first issue: 27.08.2021

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information** Other information Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines. Full text of H-Statements H302 Harmful if swallowed. H360D May damage the unborn child. H413 May cause long lasting harmful effects to aquatic life. Full text of other abbreviations Acute Tox. Acute toxicity Aquatic Chronic Long-term (chronic) aquatic hazard : Reproductive toxicity Repr. :

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory: LC50 - Lethal Concentration to 50 % of a test population: LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose): MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.5	28.09.2024	9374040-00009	Date of first issue: 27.08.2021

#### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN